What is The Beauty Health Company's granted (in shares)?

The Beauty Health Company (SKIN) reported granted (in shares) of $0.00 in Q1 2026.

What does granted (in shares) mean?

The weighted average exercise price of stock options granted to employees and directors during the reporting period. This metric reflects the company's cost of equity-based incentives and the strike price set for new option awards.

The Beauty Health Company SKIN Granted (in shares)

Granted (in shares) at other companies

SANUWAVE Health, Inc.SNWV

$27.71+1.1%

Other financials

Income statement

See full

Revenue$64.9M-6.7%

Gross profit$44.4M-8.5%

Operating income-$1.8M+85.0%

Net income-$6.6M+34.3%

EPS (diluted)-$0.05+37.5%

Balance sheet

See full

Cash & equivalents$204.4M-45.2%

Total debt$125.9M+756%

Total equity$55.2M+19.9%

Total assets$473.2M-29.8%

Cash flow

See full

Operating cash flow-$5.6M-285%

CapEx$224.0K+398%

Free cash flow-$5.8M-296%

Valuation

See full

Market cap$89.75M-61.5%

Enterprise value$11.24M-96.2%

P/S0.3×-0.4×

Profitability

See full

Gross margin64.9%+8.3pp

Operating margin-3.6%-1.6pp

Net margin-2%-0.9pp

FCF margin9.6%—

Returns & leverage

See full

Return on equity-12%-5.4pp

Debt / equity2.3×+2.0×

Current ratio1.8×-5.7×

Where this comes from

Reported directly by The Beauty Health Company in its filing.

Tagged under the XBRL concept us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice.

The official record: The Beauty Health Company’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →

Ask your AI about The Beauty Health Company's granted (in shares).

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI

Claude

Questions, answered.

What is The Beauty Health Company's granted (in shares)?: The Beauty Health Company (SKIN) reported granted (in shares) of $0.00 in Q1 2026.
What does granted (in shares) mean?: The weighted average exercise price of stock options granted to employees and directors during the reporting period. This metric reflects the company's cost of equity-based incentives and the strike price set for new option awards.